NCT05508334View on ClinicalTrials.gov

A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

81

Participants

Timeline

Start Date

January 30, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

December 30, 2025

Conditions

Advanced Solid Tumours

Interventions

DRUG

RC88

Every 2 weeks for a maximum of 2 years

Trial Locations (2)

Unknown

Remegen, Beijing

Remgenen, Beijing

All Listed Sponsors

lead

RemeGen Co., Ltd.

INDUSTRY